Larvol Delta - FORTITUDE-First-in-Human-Study-of-NG350A-an-Oncolytic-Adenoviral-Vector-Which-Expresses-an-AntiCD40-Antibody

NG-350A - PsiOxus

http://clinicaltrials.gov/ct2/show/NCT03852511

May 27, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next